Mankind Pharma
Ticker > Company >

Mankind Pharma share price

Mankind Pharma Ltd.

NSE: MANKIND BSE: 543904 SECTOR: Pharmaceuticals & Drugs  145k   439   108

2462.30
-3.25 (-0.13%)
BSE: 30 May 04:01 PM

Price Summary

Today's High

₹ 2546

Today's Low

₹ 2453.35

52 Week High

₹ 3050

52 Week Low

₹ 1910.1

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 101611.99 Cr.

Enterprise Value

₹ 100850.98 Cr.

No. of Shares

41.27 Cr.

P/E

53.93

P/B

6.94

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  354.77

CASH

₹ 761.01 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

72.7 %

EPS (TTM)

₹  45.66

Sales Growth

14%

ROE

20.98 %

ROCE

26.13%

Profit Growth

46.08 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Mankind Pharma Ltd.

Moxikind Mahacef Zenflox Cefakind Telmikind Amlokind Zolahart Overzyme Pantakind Ranidom Asthakind Combihale Nurokind Nurokind Plus Nurokind Gold Health OK Dynaglipt Glimestar Glykind-M Voglistar Unwanted-21 Days Prega News AcneStar Ring-Out Daffy Codistar Clonafit Manforce Epic Health OK Unwanted-72 AcneStar Kabz End Ring-Out Safe Kind Kaloree-1 Heal-O-Kind Calsimust Gel Multistar Liquid Calcimust Strong Liquid Nurokind-Plus Vet Injection Enerdyna Liquid Totavit Strong Powder Ceftiforce Injection Enrostrong

Index Presence

The company is present in 26 Indices.

NIFTYMIDCAP

NIFTY Midcap 100
57420
  -37.25 (-0.0648308089927774%)

NIFTY500

Nifty 500
22801.95
  -59.3999999999978 (-0.25982717556049%)

NIFTYPHARMA

Nifty Pharma
21442.05
  -147.299999999999 (-0.682280846806405%)

NIFTYMIDCAP150

Nifty Midcap 150
21125.55
  -37.6000000000022 (-0.177667313230789%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
19591.6
  -0.55000000000291 (-0.0028072467799789%)

NFTMIDSMLINCONS

Nifty MidSmall India Consumption
18906.85
  -208.800000000003 (-1.09229871858924%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
17507.4
  -11.9499999999971 (-0.0682102931900852%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
15994.95
  -42.8999999999996 (-0.26749221373189%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
15879.4
  -22.2000000000007 (-0.139608592846008%)

NFT500EQUAL

Nifty 500 Equal Weight
14097.95
  -20.0999999999985 (-0.142370936496172%)

NIFTYHEALTH

Nifty Healthcare Index
13890.4
  -99.0500000000011 (-0.708033553856668%)

NIFTY200

Nifty 200
13798.4
  -43.1499999999996 (-0.311742543284532%)

NIFTYTOTALMCAP

Nifty Total Market index
12835.2
  -30.75 (-0.239002949646161%)

SHARIAH500

Nifty500 Shariah
7038.05
  -46.4499999999998 (-0.655656715364528%)

BSE HC

S&P Bse Healthcare
42604.29
  -110.809999999998 (-0.259416459284889%)

BSE500

S&P Bse 500
35815.16
  -118.25 (-0.329080930532333%)

200EQW

BSE 200 Equal Weight
12851.51
  -60.75 (-0.470483091263652%)

BSE200

S&P Bse 200
11235.8
  -42.9900000000016 (-0.381157907896168%)

BSE1000

Bse 1000
10666.9
  -30.5900000000001 (-0.285954929614329%)

LMI250

S&P Bse 250 LargeMidCap
10647.06
  -38.8900000000012 (-0.363935822271311%)

S&P LARGEMIDCAP

S&P Bse Large MidCap
10319.66
  72.75 (0.709970127579918%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

LRGCAP

S&P Bse LargeCap
9534.24
  -35 (-0.365755274191049%)

BSE100LARGECAPTMC

S&P Bse 100 LargeCap TMC
9146.59
  -32.2099999999991 (-0.350917331241551%)

SHA500

S&P Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

BSESELECTIPO

BSE Select IPO Index
4784.92
  -0.769999999999527 (-0.0160896338876837%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year14%
3 Year18.82%
5 Year19.33%

Profit Growth

1 Year46.08%
3 Year18.91%
5 Year28.82%

ROE%

1 Year20.98%
3 Year21.02%
5 Year23.49%

ROCE %

1 Year26.13%
3 Year26.39%
5 Year30.06%

Debt/Equity

0

Price to Cash Flow

51.24

Interest Cover Ratio

150.8347

CFO/PAT (5 Yr. Avg.)

1.00656514579922

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 72.70 0.00
Dec 2024 72.71 0.00
Sep 2024 74.87 0.00
Jun 2024 74.87 0.00
Mar 2024 74.88 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 18.9145381743531% for the Past 3 years.
  • The company has shown a good revenue growth of 18.817846034388% for the Past 3 years.
  • Company has been maintaining healthy ROE of 21.0175715340708% over the past 3 years.
  • Company has been maintaining healthy ROCE of 26.3926676451921% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 150.8347.
  • The Company has been maintaining an effective average operating margins of 23.3530260459624% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -40.1079 days.
  • Company has a healthy liquidity position with current ratio of 3.4441.
  • The company has a good cash flow management; CFO/PAT stands at 1.00656514579922.
  • The company has a high promoter holding of 72.7%.

 Limitations

  • The company is trading at a high PE of 53.93.
  • The company is trading at a high EV/EBITDA of 35.5245.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 2007.47 2403.26 2529.74 2396.57 2126.59
Total Expenditure 1481.69 1831.06 1777.71 1655.64 1649.67
Operating Profit 525.78 572.2 752.03 740.93 476.92
Other Income 84.96 94.83 105.76 69.82 219.32
Interest 4.29 6.26 1.92 199.47 162.25
Depreciation 86.62 83.4 85.42 87.03 105.24
Exceptional Items 0 0 0 0 0
Profit Before Tax 519.83 577.37 770.45 524.25 428.75
Tax 75.39 93.12 168.01 107.87 46.29
Profit After Tax 444.44 484.25 602.44 416.38 382.46
Adjusted EPS (Rs) 11.09 12.09 15.04 10.09 9.27

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 4794.41 5523.18 7486.22 8127.15 9264.81
Total Expenditure 3550.47 4151.05 5647.73 6429.29 6939.19
Operating Profit 1243.94 1372.13 1838.49 1697.86 2325.61
Other Income 93.85 154.5 203.81 162.78 266.64
Interest 11.1 8.23 47.54 28.23 15.08
Depreciation 61.77 78.19 123.33 269.58 317.61
Exceptional Items 0 0 0 0 0
Profit Before Tax 1264.92 1440.21 1871.44 1562.84 2259.57
Tax 306.7 355.83 482.01 314.58 436.16
Net Profit 958.23 1084.37 1389.42 1248.26 1823.41
Adjusted EPS (Rs.) 23.92 27.07 34.68 31.16 45.52

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 40.06 40.06 40.06 40.06 40.06
Total Reserves 3611.39 4694.21 6500.39 7743.85 9583.75
Borrowings 0 0 0 0 0
Other N/C liabilities 42.84 54.11 126.98 168.12 200.54
Current liabilities 815.77 1078.91 2271.27 1419.09 1593.36
Total Liabilities 4510.06 5867.29 8938.7 9371.12 11417.71
Assets
Net Block 939.25 981.95 2921.3 3136.89 3399.07
Capital WIP 143.93 165.51 355.28 437.83 112.88
Intangible WIP 3.69 0.06 31.28 56.95 74.7
Investments 1389.51 1500.86 1657.08 2040.76 2190.62
Loans & Advances 77.6 115.59 146.3 148.86 137.64
Other N/C Assets 10.17 16.04 14.45 36.1 15.08
Current Assets 1945.9 3087.28 3813.01 3513.72 5487.71
Total Assets 4510.06 5867.29 8938.7 9371.12 11417.71
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 1264.92 1440.21 1871.44 1562.84 2259.57
Adjustment 137.23 96.74 -4.16 227 161.91
Changes in Assets & Liabilities -168.42 -156.19 -585.61 294.21 -40.95
Tax Paid -274.12 -397.38 -460.22 -285.06 -397.55
Operating Cash Flow 959.61 983.38 821.44 1798.99 1982.97
Investing Cash Flow -395.68 -1127.16 -1360.27 -1040.61 -1919.22
Financing Cash Flow -558.91 88.87 578.63 -710.41 -8.68
Net Cash Flow 5.02 -54.91 39.81 47.96 55.07

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 74.88 74.87 74.87 72.71 72.70
arjun juneja 2.04 2.04 2.04 1.98 1.98
chanakya juneja 0.97 0.97 0.97 0.94 0.94
eklavya juneja 0.97 0.97 0.97 0.94 0.94
mishka arora 0.74 0.74 0.74 0.72 0.72
poonam juneja 2.64 2.64 2.64 2.56 2.56
prem sheetal family trust... 15.42 15.41 15.41 14.97 14.97
puja juneja 2.88 2.88 2.88 2.80 2.80
rajeev juneja 1.62 1.62 1.62 1.58 1.58
rajeev juneja family trus... 19.95 19.95 19.95 19.37 19.37
ramesh juneja 1.71 1.71 1.71 1.66 1.66
ramesh juneja family trus... 20.81 20.81 20.80 20.20 20.20
ria chopra juneja 0.32 0.32 0.32 0.31 0.31
sheetal arora 4.81 4.81 4.81 4.67 4.67
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 25.12 25.13 25.13 27.29 27.30
axis mutual fund trustee ... - 1.28 - 1.06 1.29
government pension fund g... - - 1.11 1.54 1.52
nps trust- a/c sbi pensio... - - - - 1.02
sbi large & midcap fund - 1.50 - - 1.58
sbi life insurance co. lt... - - - - 1.05
sbi nifty 500 index fund - - - 1.67 -
sbi nifty midcap 150 inde... 1.52 - 1.49 - -
tata aia life insurance c... - - 1.08 - -
hema cipef (i) limited 2.22 1.62 - - -
icici prudential mutual f... - 1.00 - - -
axis mutual fund trustee ... 1.54 - - - -
icici prudential mutual f... 1.60 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Mankind Pharma reports 11% fall in Q4 consolidated net profit 22 May, 12:30 PM Mankind Pharma gets nod to incorporate wholly owned subsidiary in Sri Lanka 22 May, 11:09 AM Mankind Pharma - Quaterly Results 21 May, 6:05 PM Mankind Pharma - Quaterly Results 21 May, 6:05 PM Mankind Pharma informs about conference call 12 May, 5:34 PM Mankind Pharma gets nod to incorporate wholly owned subsidiary in Russia 15 Apr, 10:30 AM Mankind Pharma informs about compliances certificate 3 Apr, 5:10 PM Mankind Pharma informs about disclosure 1 Mar, 4:05 PM Mankind Pharma informs about outcome of board meeting 10 Feb, 5:28 PM Mankind Pharma - Quaterly Results 23 Jan, 7:18 PM Mankind Pharma - Quaterly Results 23 Jan, 7:18 PM Mankind Pharma informs about update 15 Jan, 10:10 AM Mankind Pharma, Innovent Biologics partner to commercialise Sintilimab 27 Dec, 11:18 AM Mankind Pharma informs about updates 20 Dec, 3:46 PM Mankind Pharma informs about disclosure 15 Nov, 10:38 AM Mankind Pharma informs about newspaper publication 6 Nov, 5:04 PM Mankind Pharma - Quaterly Results 5 Nov, 4:30 PM Mankind Pharma - Quaterly Results 5 Nov, 4:30 PM Mankind Pharma - Quaterly Results 5 Nov, 4:30 PM Mankind Pharma submits intimation of board meeting 25 Oct, 5:20 PM Mankind Pharma completes transaction to acquire 100% stake in Bharat Serums and Vaccines 24 Oct, 9:39 AM Mankind Pharma informs about allotment of non-convertible debentures 16 Oct, 4:08 PM Mankind Pharma to transfer OTC business undertaking to MCPPL 4 Sep, 9:29 AM Mankind Pharma informs about presentation 20 Aug, 9:38 AM Mankind Pharma informs about allotment under ESOP 14 Aug, 5:13 PM Mankind Pharma informs about investors meet 7 Aug, 11:57 AM Mankind Pharma’s Q1FY25 consolidated net profit surges by 10% 31 Jul, 3:57 PM Mankind Pharma - Quaterly Results 31 Jul, 2:47 PM Mankind Pharma - Quaterly Results 31 Jul, 2:47 PM Mankind Pharma - Quaterly Results 31 Jul, 2:47 PM Mankind Pharma inks pact to acquire 100% stake in BSV 26 Jul, 10:30 AM Mankind Pharma informs about change in time of conference call 26 Jul, 9:58 AM Mankind Pharma informs about newspaper advertisement 10 Jul, 2:05 PM Mankind Pharma informs about transcript of conference call 22 May, 5:12 PM Mankind Pharma informs about newspaper publication 16 May, 4:51 PM Mankind Pharma reports 62% rise in Q4 consolidated net profit 16 May, 12:22 PM Mankind Pharma gets nod to raise funds through various modes 16 May, 11:38 AM Mankind Pharma - Quaterly Results 15 May, 6:17 PM Mankind Pharma - Quaterly Results 15 May, 6:17 PM Mankind Pharma - Quaterly Results 15 May, 6:17 PM Mankind Pharma informs about allotment under ESOP 10 May, 9:45 AM Mankind Pharma informs about investor meetings 14 Mar, 12:48 PM Mankind Pharma informs about press release 11 Mar, 4:57 PM Mankind Pharma inks pact with AstraZeneca Pharma India 11 Mar, 4:25 PM Mankind Pharma’s promoters sell 1.62% stake in company 9 Feb, 2:58 PM Mankind Pharma - Quaterly Results 31 Jan, 5:32 PM Mankind Pharma - Quaterly Results 31 Jan, 5:32 PM Mankind Pharma - Quaterly Results 31 Jan, 5:32 PM Mankind Pharma informs about analyst meet 2 Jan, 3:17 PM Mankind Pharma makes investment in Actimed Therapeutics 18 Dec, 10:22 AM

Mankind Pharma Stock Price Analysis and Quick Research Report. Is Mankind Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Mankind Pharma and its performance over the period of time. Mankind Pharma stock price today is Rs 2467.7.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Mankind Pharma cash from the operating activity was Rs 1982.9732 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Mankind Pharma has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Mankind Pharma , the EPS growth was 46.0765 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Mankind Pharma has OPM of 25.1015927548557 % which is a good sign for profitability.
     
  • ROE: Mankind Pharma have a healthy ROE of 20.9775 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Mankind Pharma is Rs 2467.7. One can use valuation calculators of ticker to know if Mankind Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Mankind Pharma

Mankind Pharma Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Mankind Pharma Ltd. is a reputed pharmaceutical company that specializes in the development, production, and marketing of high-quality generic medicines. Established in XXXX, the company has since grown to become one of the leading players in the Indian pharmaceutical industry. Mankind Pharma operates with a vision to provide affordable and accessible healthcare solutions to people across the globe.

Mankind Pharma Ltd. - Share Price

Check the latest share price of Mankind Pharma Ltd. and stay updated with real-time market fluctuations. Our pre-built screening tools allow you to track the stock price, monitor trends, and make informed investment decisions.

Mankind Pharma Ltd. - Balance Sheet

The balance sheet of Mankind Pharma Ltd. provides a snapshot of the company's financial position. Analyze the company's assets, liabilities, and equity to gain insights into its overall financial health. We offer premium features such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis to help you calculate fair value.

Mankind Pharma Ltd. - Annual Report

Access the annual reports of Mankind Pharma Ltd. on our website. These reports offer a comprehensive overview of the company's performance, achievements, and future plans. Gain valuable insights into the company's strategies, growth trajectory, and competitive advantage.

Mankind Pharma Ltd. - Dividend

Stay updated with the company's dividend history and payout ratios. Mankind Pharma Ltd. has a track record of consistently rewarding its shareholders through dividends. Our website provides downloadable resources such as dividend history and financial statements for your analysis.

Mankind Pharma Ltd. - Quarterly Result

Get access to the latest quarterly results of Mankind Pharma Ltd. Track the company's revenue, profit, and other key financial metrics to gauge its performance. Our premium features enable you to analyze these results in conjunction with our comprehensive tools for fair value calculation.

Mankind Pharma Ltd. - Stock Price

Monitor the stock price of Mankind Pharma Ltd. and keep track of its historical performance. Our price charts provide a visual representation of the stock's movement over time. Utilize our pre-built screening tools to identify trends, patterns, and potential investment opportunities.

Mankind Pharma Ltd. - News

Stay updated with the latest news and developments related to Mankind Pharma Ltd. Our website provides curated news articles that cover the company's activities, regulatory updates, product launches, and industry trends. Stay informed and make well-informed investment decisions.

Mankind Pharma Ltd. - Concall Transcripts

Access the conference call transcripts of Mankind Pharma Ltd. These transcripts provide a detailed account of the discussions and presentations made during the company's conference calls. Stay informed about management's outlook, strategic initiatives, and future plans.

Mankind Pharma Ltd. - Investor Presentations

Explore the investor presentations of Mankind Pharma Ltd. These presentations offer valuable insights into the company's operations, growth prospects, and market dynamics. Access downloadable resources on our website to stay updated with the latest investor presentations.

Mankind Pharma Ltd. - Promoters

Learn about the promoters of Mankind Pharma Ltd. and their contribution to the company's success. Understand their vision, leadership style, and strategic direction to assess the stability and long-term potential of the company.

Mankind Pharma Ltd. - Shareholders

Discover the major shareholders of Mankind Pharma Ltd. and their significance in the company's ownership structure. Gain insights into the involvement of institutional investors and public shareholders, which play a crucial role in determining the company's governance and market dynamics.

Remember to visit our website for downloadable resources such as annual reports, concall transcripts, investor presentations, credit ratings, and research reports. Our pre-built screening tools and premium features provide you with the necessary tools to analyze and make informed investment decisions.

Read More
X